Global Neuromyelitis Optica Drug Supply, Demand and Key Producers, 2026-2032
The global Neuromyelitis Optica Drug market size is expected to reach $ 64.33 million by 2032, rising at a market growth of 2.9% CAGR during the forecast period (2026-2032).
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord. Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
The Neuromyelitis Optica (NMO) drug market is being significantly driven by the rising prevalence and improved diagnosis of this rare autoimmune disorder, also known as Neuromyelitis Optica Spectrum Disorder (NMOSD). Increased awareness among healthcare professionals, coupled with advancements in diagnostic technologies such as AQP4-IgG antibody testing, has led to earlier and more accurate diagnosis of NMO, thereby increasing the number of patients eligible for treatment. Furthermore, the approval of targeted therapies like eculizumab, inebilizumab, and satralizumab in recent years has transformed the treatment landscape, offering more effective and specific interventions compared to traditional immunosuppressants. These breakthroughs have not only improved patient outcomes but have also stimulated investment and innovation in NMO drug development. The growing focus on orphan diseases by pharmaceutical companies, supported by favorable regulatory incentives such as orphan drug designations and fast-track approvals, is further fueling market growth. In addition, increasing healthcare expenditure, especially in developed regions, and a stronger patient advocacy movement are contributing to greater access to treatment and awareness about this once-overlooked condition.
Despite promising developments, the NMO drug market faces several challenges that may hinder its long-term growth. First, the high cost of newly approved biologic therapies poses a significant barrier to access, particularly in low- and middle-income countries where reimbursement systems are weak or nonexistent. The pricing of drugs like eculizumab, which can cost hundreds of thousands of dollars per year, places a heavy burden on both healthcare systems and patients, potentially limiting widespread adoption. Additionally, NMO is a rare and complex disease, which makes it difficult to recruit sufficient participants for large-scale clinical trials, slowing the pace of drug development and innovation. The heterogeneity of disease presentation and overlapping symptoms with multiple sclerosis also pose diagnostic challenges, which can lead to misdiagnosis and inappropriate treatment. Moreover, long-term safety data for newer therapies are still limited, which may create hesitation among clinicians and regulatory bodies when adopting these treatments on a broader scale. Lastly, the market remains highly specialized, with few pharmaceutical players involved, leading to limited competition and potential supply chain vulnerabilities. Addressing these issues will be essential to ensuring that recent advancements in NMO treatment translate into improved outcomes for patients across different healthcare environments.
This report studies the global Neuromyelitis Optica Drug demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Neuromyelitis Optica Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Neuromyelitis Optica Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Neuromyelitis Optica Drug total market, 2021-2032, (USD Million)
Global Neuromyelitis Optica Drug total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Neuromyelitis Optica Drug total market, key domestic companies, and share, (USD Million)
Global Neuromyelitis Optica Drug revenue by player, revenue and market share 2021-2026, (USD Million)
Global Neuromyelitis Optica Drug total market by Type, CAGR, 2021-2032, (USD Million)
Global Neuromyelitis Optica Drug total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Neuromyelitis Optica Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Neuromyelitis Optica Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Neuromyelitis Optica Drug Market, By Region:
1. How big is the global Neuromyelitis Optica Drug market?
2. What is the demand of the global Neuromyelitis Optica Drug market?
3. What is the year over year growth of the global Neuromyelitis Optica Drug market?
4. What is the total value of the global Neuromyelitis Optica Drug market?
5. Who are the Major Players in the global Neuromyelitis Optica Drug market?
6. What are the growth factors driving the market demand?
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord. Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
The Neuromyelitis Optica (NMO) drug market is being significantly driven by the rising prevalence and improved diagnosis of this rare autoimmune disorder, also known as Neuromyelitis Optica Spectrum Disorder (NMOSD). Increased awareness among healthcare professionals, coupled with advancements in diagnostic technologies such as AQP4-IgG antibody testing, has led to earlier and more accurate diagnosis of NMO, thereby increasing the number of patients eligible for treatment. Furthermore, the approval of targeted therapies like eculizumab, inebilizumab, and satralizumab in recent years has transformed the treatment landscape, offering more effective and specific interventions compared to traditional immunosuppressants. These breakthroughs have not only improved patient outcomes but have also stimulated investment and innovation in NMO drug development. The growing focus on orphan diseases by pharmaceutical companies, supported by favorable regulatory incentives such as orphan drug designations and fast-track approvals, is further fueling market growth. In addition, increasing healthcare expenditure, especially in developed regions, and a stronger patient advocacy movement are contributing to greater access to treatment and awareness about this once-overlooked condition.
Despite promising developments, the NMO drug market faces several challenges that may hinder its long-term growth. First, the high cost of newly approved biologic therapies poses a significant barrier to access, particularly in low- and middle-income countries where reimbursement systems are weak or nonexistent. The pricing of drugs like eculizumab, which can cost hundreds of thousands of dollars per year, places a heavy burden on both healthcare systems and patients, potentially limiting widespread adoption. Additionally, NMO is a rare and complex disease, which makes it difficult to recruit sufficient participants for large-scale clinical trials, slowing the pace of drug development and innovation. The heterogeneity of disease presentation and overlapping symptoms with multiple sclerosis also pose diagnostic challenges, which can lead to misdiagnosis and inappropriate treatment. Moreover, long-term safety data for newer therapies are still limited, which may create hesitation among clinicians and regulatory bodies when adopting these treatments on a broader scale. Lastly, the market remains highly specialized, with few pharmaceutical players involved, leading to limited competition and potential supply chain vulnerabilities. Addressing these issues will be essential to ensuring that recent advancements in NMO treatment translate into improved outcomes for patients across different healthcare environments.
This report studies the global Neuromyelitis Optica Drug demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Neuromyelitis Optica Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Neuromyelitis Optica Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Neuromyelitis Optica Drug total market, 2021-2032, (USD Million)
Global Neuromyelitis Optica Drug total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Neuromyelitis Optica Drug total market, key domestic companies, and share, (USD Million)
Global Neuromyelitis Optica Drug revenue by player, revenue and market share 2021-2026, (USD Million)
Global Neuromyelitis Optica Drug total market by Type, CAGR, 2021-2032, (USD Million)
Global Neuromyelitis Optica Drug total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Neuromyelitis Optica Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Neuromyelitis Optica Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Neuromyelitis Optica Drug Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Glucocorticoids
- Immunotherapies
- Others
- Acute Attack
- Remission Prophylactic Treatment
- Pfizer
- Fresenius
- Teva
- Sandoz
- Intas
- Gyjtrs
- NANG KUANG
- Tianjin Kingyork
- Baxter
- CSL
- Grifols
- Octapharma
- CBOP
1. How big is the global Neuromyelitis Optica Drug market?
2. What is the demand of the global Neuromyelitis Optica Drug market?
3. What is the year over year growth of the global Neuromyelitis Optica Drug market?
4. What is the total value of the global Neuromyelitis Optica Drug market?
5. Who are the Major Players in the global Neuromyelitis Optica Drug market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Neuromyelitis Optica Drug Introduction
1.2 World Neuromyelitis Optica Drug Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Neuromyelitis Optica Drug Total Market by Region (by Headquarter Location)
1.3.1 World Neuromyelitis Optica Drug Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Neuromyelitis Optica Drug Revenue (2021-2032)
1.3.3 China Based Company Neuromyelitis Optica Drug Revenue (2021-2032)
1.3.4 Europe Based Company Neuromyelitis Optica Drug Revenue (2021-2032)
1.3.5 Japan Based Company Neuromyelitis Optica Drug Revenue (2021-2032)
1.3.6 South Korea Based Company Neuromyelitis Optica Drug Revenue (2021-2032)
1.3.7 ASEAN Based Company Neuromyelitis Optica Drug Revenue (2021-2032)
1.3.8 India Based Company Neuromyelitis Optica Drug Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Neuromyelitis Optica Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Neuromyelitis Optica Drug Consumption Value (2021-2032)
2.2 World Neuromyelitis Optica Drug Consumption Value by Region
2.2.1 World Neuromyelitis Optica Drug Consumption Value by Region (2021-2026)
2.2.2 World Neuromyelitis Optica Drug Consumption Value Forecast by Region (2027-2032)
2.3 United States Neuromyelitis Optica Drug Consumption Value (2021-2032)
2.4 China Neuromyelitis Optica Drug Consumption Value (2021-2032)
2.5 Europe Neuromyelitis Optica Drug Consumption Value (2021-2032)
2.6 Japan Neuromyelitis Optica Drug Consumption Value (2021-2032)
2.7 South Korea Neuromyelitis Optica Drug Consumption Value (2021-2032)
2.8 ASEAN Neuromyelitis Optica Drug Consumption Value (2021-2032)
2.9 India Neuromyelitis Optica Drug Consumption Value (2021-2032)
3 WORLD NEUROMYELITIS OPTICA DRUG COMPANIES COMPETITIVE ANALYSIS
3.1 World Neuromyelitis Optica Drug Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Neuromyelitis Optica Drug Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Neuromyelitis Optica Drug in 2025
3.2.3 Global Concentration Ratios (CR8) for Neuromyelitis Optica Drug in 2025
3.3 Neuromyelitis Optica Drug Company Evaluation Quadrant
3.4 Neuromyelitis Optica Drug Market: Overall Company Footprint Analysis
3.4.1 Neuromyelitis Optica Drug Market: Region Footprint
3.4.2 Neuromyelitis Optica Drug Market: Company Product Type Footprint
3.4.3 Neuromyelitis Optica Drug Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Neuromyelitis Optica Drug Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Neuromyelitis Optica Drug Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Neuromyelitis Optica Drug Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Neuromyelitis Optica Drug Consumption Value Comparison
4.2.1 United States VS China: Neuromyelitis Optica Drug Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Neuromyelitis Optica Drug Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Neuromyelitis Optica Drug Companies and Market Share, 2021-2026
4.3.1 United States Based Neuromyelitis Optica Drug Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Neuromyelitis Optica Drug Revenue, (2021-2026)
4.4 China Based Companies Neuromyelitis Optica Drug Revenue and Market Share, 2021-2026
4.4.1 China Based Neuromyelitis Optica Drug Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Neuromyelitis Optica Drug Revenue, (2021-2026)
4.5 Rest of World Based Neuromyelitis Optica Drug Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Neuromyelitis Optica Drug Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Neuromyelitis Optica Drug Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Neuromyelitis Optica Drug Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Glucocorticoids
5.2.2 Immunotherapies
5.2.3 Others
5.3 Market Segment by Type
5.3.1 World Neuromyelitis Optica Drug Market Size by Type (2021-2026)
5.3.2 World Neuromyelitis Optica Drug Market Size by Type (2027-2032)
5.3.3 World Neuromyelitis Optica Drug Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Neuromyelitis Optica Drug Market Size Overview by Application: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Application
6.2.1 Acute Attack
6.2.2 Remission Prophylactic Treatment
6.3 Market Segment by Application
6.3.1 World Neuromyelitis Optica Drug Market Size by Application (2021-2026)
6.3.2 World Neuromyelitis Optica Drug Market Size by Application (2027-2032)
6.3.3 World Neuromyelitis Optica Drug Market Size Market Share by Application (2021-2032)
7 COMPANY PROFILES
7.1 Pfizer
7.1.1 Pfizer Details
7.1.2 Pfizer Major Business
7.1.3 Pfizer Neuromyelitis Optica Drug Product and Services
7.1.4 Pfizer Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.1.5 Pfizer Recent Developments/Updates
7.1.6 Pfizer Competitive Strengths & Weaknesses
7.2 Fresenius
7.2.1 Fresenius Details
7.2.2 Fresenius Major Business
7.2.3 Fresenius Neuromyelitis Optica Drug Product and Services
7.2.4 Fresenius Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.2.5 Fresenius Recent Developments/Updates
7.2.6 Fresenius Competitive Strengths & Weaknesses
7.3 Teva
7.3.1 Teva Details
7.3.2 Teva Major Business
7.3.3 Teva Neuromyelitis Optica Drug Product and Services
7.3.4 Teva Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.3.5 Teva Recent Developments/Updates
7.3.6 Teva Competitive Strengths & Weaknesses
7.4 Sandoz
7.4.1 Sandoz Details
7.4.2 Sandoz Major Business
7.4.3 Sandoz Neuromyelitis Optica Drug Product and Services
7.4.4 Sandoz Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.4.5 Sandoz Recent Developments/Updates
7.4.6 Sandoz Competitive Strengths & Weaknesses
7.5 Intas
7.5.1 Intas Details
7.5.2 Intas Major Business
7.5.3 Intas Neuromyelitis Optica Drug Product and Services
7.5.4 Intas Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.5.5 Intas Recent Developments/Updates
7.5.6 Intas Competitive Strengths & Weaknesses
7.6 Gyjtrs
7.6.1 Gyjtrs Details
7.6.2 Gyjtrs Major Business
7.6.3 Gyjtrs Neuromyelitis Optica Drug Product and Services
7.6.4 Gyjtrs Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.6.5 Gyjtrs Recent Developments/Updates
7.6.6 Gyjtrs Competitive Strengths & Weaknesses
7.7 NANG KUANG
7.7.1 NANG KUANG Details
7.7.2 NANG KUANG Major Business
7.7.3 NANG KUANG Neuromyelitis Optica Drug Product and Services
7.7.4 NANG KUANG Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.7.5 NANG KUANG Recent Developments/Updates
7.7.6 NANG KUANG Competitive Strengths & Weaknesses
7.8 Tianjin Kingyork
7.8.1 Tianjin Kingyork Details
7.8.2 Tianjin Kingyork Major Business
7.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Product and Services
7.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.8.5 Tianjin Kingyork Recent Developments/Updates
7.8.6 Tianjin Kingyork Competitive Strengths & Weaknesses
7.9 Baxter
7.9.1 Baxter Details
7.9.2 Baxter Major Business
7.9.3 Baxter Neuromyelitis Optica Drug Product and Services
7.9.4 Baxter Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.9.5 Baxter Recent Developments/Updates
7.9.6 Baxter Competitive Strengths & Weaknesses
7.10 CSL
7.10.1 CSL Details
7.10.2 CSL Major Business
7.10.3 CSL Neuromyelitis Optica Drug Product and Services
7.10.4 CSL Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.10.5 CSL Recent Developments/Updates
7.10.6 CSL Competitive Strengths & Weaknesses
7.11 Grifols
7.11.1 Grifols Details
7.11.2 Grifols Major Business
7.11.3 Grifols Neuromyelitis Optica Drug Product and Services
7.11.4 Grifols Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.11.5 Grifols Recent Developments/Updates
7.11.6 Grifols Competitive Strengths & Weaknesses
7.12 Octapharma
7.12.1 Octapharma Details
7.12.2 Octapharma Major Business
7.12.3 Octapharma Neuromyelitis Optica Drug Product and Services
7.12.4 Octapharma Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.12.5 Octapharma Recent Developments/Updates
7.12.6 Octapharma Competitive Strengths & Weaknesses
7.13 CBOP
7.13.1 CBOP Details
7.13.2 CBOP Major Business
7.13.3 CBOP Neuromyelitis Optica Drug Product and Services
7.13.4 CBOP Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.13.5 CBOP Recent Developments/Updates
7.13.6 CBOP Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Neuromyelitis Optica Drug Industry Chain
8.2 Neuromyelitis Optica Drug Upstream Analysis
8.3 Neuromyelitis Optica Drug Midstream Analysis
8.4 Neuromyelitis Optica Drug Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Neuromyelitis Optica Drug Introduction
1.2 World Neuromyelitis Optica Drug Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Neuromyelitis Optica Drug Total Market by Region (by Headquarter Location)
1.3.1 World Neuromyelitis Optica Drug Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Neuromyelitis Optica Drug Revenue (2021-2032)
1.3.3 China Based Company Neuromyelitis Optica Drug Revenue (2021-2032)
1.3.4 Europe Based Company Neuromyelitis Optica Drug Revenue (2021-2032)
1.3.5 Japan Based Company Neuromyelitis Optica Drug Revenue (2021-2032)
1.3.6 South Korea Based Company Neuromyelitis Optica Drug Revenue (2021-2032)
1.3.7 ASEAN Based Company Neuromyelitis Optica Drug Revenue (2021-2032)
1.3.8 India Based Company Neuromyelitis Optica Drug Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Neuromyelitis Optica Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Neuromyelitis Optica Drug Consumption Value (2021-2032)
2.2 World Neuromyelitis Optica Drug Consumption Value by Region
2.2.1 World Neuromyelitis Optica Drug Consumption Value by Region (2021-2026)
2.2.2 World Neuromyelitis Optica Drug Consumption Value Forecast by Region (2027-2032)
2.3 United States Neuromyelitis Optica Drug Consumption Value (2021-2032)
2.4 China Neuromyelitis Optica Drug Consumption Value (2021-2032)
2.5 Europe Neuromyelitis Optica Drug Consumption Value (2021-2032)
2.6 Japan Neuromyelitis Optica Drug Consumption Value (2021-2032)
2.7 South Korea Neuromyelitis Optica Drug Consumption Value (2021-2032)
2.8 ASEAN Neuromyelitis Optica Drug Consumption Value (2021-2032)
2.9 India Neuromyelitis Optica Drug Consumption Value (2021-2032)
3 WORLD NEUROMYELITIS OPTICA DRUG COMPANIES COMPETITIVE ANALYSIS
3.1 World Neuromyelitis Optica Drug Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Neuromyelitis Optica Drug Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Neuromyelitis Optica Drug in 2025
3.2.3 Global Concentration Ratios (CR8) for Neuromyelitis Optica Drug in 2025
3.3 Neuromyelitis Optica Drug Company Evaluation Quadrant
3.4 Neuromyelitis Optica Drug Market: Overall Company Footprint Analysis
3.4.1 Neuromyelitis Optica Drug Market: Region Footprint
3.4.2 Neuromyelitis Optica Drug Market: Company Product Type Footprint
3.4.3 Neuromyelitis Optica Drug Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Neuromyelitis Optica Drug Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Neuromyelitis Optica Drug Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Neuromyelitis Optica Drug Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Neuromyelitis Optica Drug Consumption Value Comparison
4.2.1 United States VS China: Neuromyelitis Optica Drug Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Neuromyelitis Optica Drug Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Neuromyelitis Optica Drug Companies and Market Share, 2021-2026
4.3.1 United States Based Neuromyelitis Optica Drug Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Neuromyelitis Optica Drug Revenue, (2021-2026)
4.4 China Based Companies Neuromyelitis Optica Drug Revenue and Market Share, 2021-2026
4.4.1 China Based Neuromyelitis Optica Drug Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Neuromyelitis Optica Drug Revenue, (2021-2026)
4.5 Rest of World Based Neuromyelitis Optica Drug Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Neuromyelitis Optica Drug Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Neuromyelitis Optica Drug Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Neuromyelitis Optica Drug Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Glucocorticoids
5.2.2 Immunotherapies
5.2.3 Others
5.3 Market Segment by Type
5.3.1 World Neuromyelitis Optica Drug Market Size by Type (2021-2026)
5.3.2 World Neuromyelitis Optica Drug Market Size by Type (2027-2032)
5.3.3 World Neuromyelitis Optica Drug Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Neuromyelitis Optica Drug Market Size Overview by Application: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Application
6.2.1 Acute Attack
6.2.2 Remission Prophylactic Treatment
6.3 Market Segment by Application
6.3.1 World Neuromyelitis Optica Drug Market Size by Application (2021-2026)
6.3.2 World Neuromyelitis Optica Drug Market Size by Application (2027-2032)
6.3.3 World Neuromyelitis Optica Drug Market Size Market Share by Application (2021-2032)
7 COMPANY PROFILES
7.1 Pfizer
7.1.1 Pfizer Details
7.1.2 Pfizer Major Business
7.1.3 Pfizer Neuromyelitis Optica Drug Product and Services
7.1.4 Pfizer Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.1.5 Pfizer Recent Developments/Updates
7.1.6 Pfizer Competitive Strengths & Weaknesses
7.2 Fresenius
7.2.1 Fresenius Details
7.2.2 Fresenius Major Business
7.2.3 Fresenius Neuromyelitis Optica Drug Product and Services
7.2.4 Fresenius Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.2.5 Fresenius Recent Developments/Updates
7.2.6 Fresenius Competitive Strengths & Weaknesses
7.3 Teva
7.3.1 Teva Details
7.3.2 Teva Major Business
7.3.3 Teva Neuromyelitis Optica Drug Product and Services
7.3.4 Teva Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.3.5 Teva Recent Developments/Updates
7.3.6 Teva Competitive Strengths & Weaknesses
7.4 Sandoz
7.4.1 Sandoz Details
7.4.2 Sandoz Major Business
7.4.3 Sandoz Neuromyelitis Optica Drug Product and Services
7.4.4 Sandoz Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.4.5 Sandoz Recent Developments/Updates
7.4.6 Sandoz Competitive Strengths & Weaknesses
7.5 Intas
7.5.1 Intas Details
7.5.2 Intas Major Business
7.5.3 Intas Neuromyelitis Optica Drug Product and Services
7.5.4 Intas Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.5.5 Intas Recent Developments/Updates
7.5.6 Intas Competitive Strengths & Weaknesses
7.6 Gyjtrs
7.6.1 Gyjtrs Details
7.6.2 Gyjtrs Major Business
7.6.3 Gyjtrs Neuromyelitis Optica Drug Product and Services
7.6.4 Gyjtrs Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.6.5 Gyjtrs Recent Developments/Updates
7.6.6 Gyjtrs Competitive Strengths & Weaknesses
7.7 NANG KUANG
7.7.1 NANG KUANG Details
7.7.2 NANG KUANG Major Business
7.7.3 NANG KUANG Neuromyelitis Optica Drug Product and Services
7.7.4 NANG KUANG Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.7.5 NANG KUANG Recent Developments/Updates
7.7.6 NANG KUANG Competitive Strengths & Weaknesses
7.8 Tianjin Kingyork
7.8.1 Tianjin Kingyork Details
7.8.2 Tianjin Kingyork Major Business
7.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Product and Services
7.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.8.5 Tianjin Kingyork Recent Developments/Updates
7.8.6 Tianjin Kingyork Competitive Strengths & Weaknesses
7.9 Baxter
7.9.1 Baxter Details
7.9.2 Baxter Major Business
7.9.3 Baxter Neuromyelitis Optica Drug Product and Services
7.9.4 Baxter Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.9.5 Baxter Recent Developments/Updates
7.9.6 Baxter Competitive Strengths & Weaknesses
7.10 CSL
7.10.1 CSL Details
7.10.2 CSL Major Business
7.10.3 CSL Neuromyelitis Optica Drug Product and Services
7.10.4 CSL Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.10.5 CSL Recent Developments/Updates
7.10.6 CSL Competitive Strengths & Weaknesses
7.11 Grifols
7.11.1 Grifols Details
7.11.2 Grifols Major Business
7.11.3 Grifols Neuromyelitis Optica Drug Product and Services
7.11.4 Grifols Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.11.5 Grifols Recent Developments/Updates
7.11.6 Grifols Competitive Strengths & Weaknesses
7.12 Octapharma
7.12.1 Octapharma Details
7.12.2 Octapharma Major Business
7.12.3 Octapharma Neuromyelitis Optica Drug Product and Services
7.12.4 Octapharma Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.12.5 Octapharma Recent Developments/Updates
7.12.6 Octapharma Competitive Strengths & Weaknesses
7.13 CBOP
7.13.1 CBOP Details
7.13.2 CBOP Major Business
7.13.3 CBOP Neuromyelitis Optica Drug Product and Services
7.13.4 CBOP Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
7.13.5 CBOP Recent Developments/Updates
7.13.6 CBOP Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Neuromyelitis Optica Drug Industry Chain
8.2 Neuromyelitis Optica Drug Upstream Analysis
8.3 Neuromyelitis Optica Drug Midstream Analysis
8.4 Neuromyelitis Optica Drug Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Neuromyelitis Optica Drug Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Neuromyelitis Optica Drug Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Neuromyelitis Optica Drug Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Neuromyelitis Optica Drug Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Neuromyelitis Optica Drug Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Neuromyelitis Optica Drug Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Neuromyelitis Optica Drug Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Neuromyelitis Optica Drug Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Neuromyelitis Optica Drug Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Neuromyelitis Optica Drug Players in 2025
Table 12. World Neuromyelitis Optica Drug Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Neuromyelitis Optica Drug Company Evaluation Quadrant
Table 14. Head Office of Key Neuromyelitis Optica Drug Players
Table 15. Neuromyelitis Optica Drug Market: Company Product Type Footprint
Table 16. Neuromyelitis Optica Drug Market: Company Product Application Footprint
Table 17. Neuromyelitis Optica Drug Mergers & Acquisitions Activity
Table 18. United States VS China Neuromyelitis Optica Drug Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Neuromyelitis Optica Drug Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Neuromyelitis Optica Drug Companies, Headquarters (States, Country)
Table 21. United States Based Companies Neuromyelitis Optica Drug Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Neuromyelitis Optica Drug Revenue Market Share (2021-2026)
Table 23. China Based Neuromyelitis Optica Drug Companies, Headquarters (Province, Country)
Table 24. China Based Companies Neuromyelitis Optica Drug Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Neuromyelitis Optica Drug Revenue Market Share (2021-2026)
Table 26. Rest of World Based Neuromyelitis Optica Drug Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Neuromyelitis Optica Drug Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Neuromyelitis Optica Drug Revenue Market Share (2021-2026)
Table 29. World Neuromyelitis Optica Drug Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Neuromyelitis Optica Drug Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Neuromyelitis Optica Drug Market Size by Type (2027-2032) & (USD Million)
Table 32. World Neuromyelitis Optica Drug Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 33. World Neuromyelitis Optica Drug Market Size by Application (2021-2026) & (USD Million)
Table 34. World Neuromyelitis Optica Drug Market Size by Application (2027-2032) & (USD Million)
Table 35. Pfizer Basic Information, Manufacturing Base and Competitors
Table 36. Pfizer Major Business
Table 37. Pfizer Neuromyelitis Optica Drug Product and Services
Table 38. Pfizer Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 39. Pfizer Recent Developments/Updates
Table 40. Pfizer Competitive Strengths & Weaknesses
Table 41. Fresenius Basic Information, Manufacturing Base and Competitors
Table 42. Fresenius Major Business
Table 43. Fresenius Neuromyelitis Optica Drug Product and Services
Table 44. Fresenius Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Fresenius Recent Developments/Updates
Table 46. Fresenius Competitive Strengths & Weaknesses
Table 47. Teva Basic Information, Manufacturing Base and Competitors
Table 48. Teva Major Business
Table 49. Teva Neuromyelitis Optica Drug Product and Services
Table 50. Teva Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Teva Recent Developments/Updates
Table 52. Teva Competitive Strengths & Weaknesses
Table 53. Sandoz Basic Information, Manufacturing Base and Competitors
Table 54. Sandoz Major Business
Table 55. Sandoz Neuromyelitis Optica Drug Product and Services
Table 56. Sandoz Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Sandoz Recent Developments/Updates
Table 58. Sandoz Competitive Strengths & Weaknesses
Table 59. Intas Basic Information, Manufacturing Base and Competitors
Table 60. Intas Major Business
Table 61. Intas Neuromyelitis Optica Drug Product and Services
Table 62. Intas Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Intas Recent Developments/Updates
Table 64. Intas Competitive Strengths & Weaknesses
Table 65. Gyjtrs Basic Information, Manufacturing Base and Competitors
Table 66. Gyjtrs Major Business
Table 67. Gyjtrs Neuromyelitis Optica Drug Product and Services
Table 68. Gyjtrs Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Gyjtrs Recent Developments/Updates
Table 70. Gyjtrs Competitive Strengths & Weaknesses
Table 71. NANG KUANG Basic Information, Manufacturing Base and Competitors
Table 72. NANG KUANG Major Business
Table 73. NANG KUANG Neuromyelitis Optica Drug Product and Services
Table 74. NANG KUANG Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. NANG KUANG Recent Developments/Updates
Table 76. NANG KUANG Competitive Strengths & Weaknesses
Table 77. Tianjin Kingyork Basic Information, Manufacturing Base and Competitors
Table 78. Tianjin Kingyork Major Business
Table 79. Tianjin Kingyork Neuromyelitis Optica Drug Product and Services
Table 80. Tianjin Kingyork Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Tianjin Kingyork Recent Developments/Updates
Table 82. Tianjin Kingyork Competitive Strengths & Weaknesses
Table 83. Baxter Basic Information, Manufacturing Base and Competitors
Table 84. Baxter Major Business
Table 85. Baxter Neuromyelitis Optica Drug Product and Services
Table 86. Baxter Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Baxter Recent Developments/Updates
Table 88. Baxter Competitive Strengths & Weaknesses
Table 89. CSL Basic Information, Manufacturing Base and Competitors
Table 90. CSL Major Business
Table 91. CSL Neuromyelitis Optica Drug Product and Services
Table 92. CSL Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. CSL Recent Developments/Updates
Table 94. CSL Competitive Strengths & Weaknesses
Table 95. Grifols Basic Information, Manufacturing Base and Competitors
Table 96. Grifols Major Business
Table 97. Grifols Neuromyelitis Optica Drug Product and Services
Table 98. Grifols Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Grifols Recent Developments/Updates
Table 100. Grifols Competitive Strengths & Weaknesses
Table 101. Octapharma Basic Information, Manufacturing Base and Competitors
Table 102. Octapharma Major Business
Table 103. Octapharma Neuromyelitis Optica Drug Product and Services
Table 104. Octapharma Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Octapharma Recent Developments/Updates
Table 106. Octapharma Competitive Strengths & Weaknesses
Table 107. CBOP Basic Information, Manufacturing Base and Competitors
Table 108. CBOP Major Business
Table 109. CBOP Neuromyelitis Optica Drug Product and Services
Table 110. CBOP Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. CBOP Recent Developments/Updates
Table 112. CBOP Competitive Strengths & Weaknesses
Table 113. Global Key Players of Neuromyelitis Optica Drug Upstream (Raw Materials)
Table 114. Global Neuromyelitis Optica Drug Typical Customers
Table 1. World Neuromyelitis Optica Drug Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Neuromyelitis Optica Drug Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Neuromyelitis Optica Drug Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Neuromyelitis Optica Drug Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Neuromyelitis Optica Drug Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Neuromyelitis Optica Drug Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Neuromyelitis Optica Drug Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Neuromyelitis Optica Drug Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Neuromyelitis Optica Drug Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Neuromyelitis Optica Drug Players in 2025
Table 12. World Neuromyelitis Optica Drug Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Neuromyelitis Optica Drug Company Evaluation Quadrant
Table 14. Head Office of Key Neuromyelitis Optica Drug Players
Table 15. Neuromyelitis Optica Drug Market: Company Product Type Footprint
Table 16. Neuromyelitis Optica Drug Market: Company Product Application Footprint
Table 17. Neuromyelitis Optica Drug Mergers & Acquisitions Activity
Table 18. United States VS China Neuromyelitis Optica Drug Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Neuromyelitis Optica Drug Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Neuromyelitis Optica Drug Companies, Headquarters (States, Country)
Table 21. United States Based Companies Neuromyelitis Optica Drug Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Neuromyelitis Optica Drug Revenue Market Share (2021-2026)
Table 23. China Based Neuromyelitis Optica Drug Companies, Headquarters (Province, Country)
Table 24. China Based Companies Neuromyelitis Optica Drug Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Neuromyelitis Optica Drug Revenue Market Share (2021-2026)
Table 26. Rest of World Based Neuromyelitis Optica Drug Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Neuromyelitis Optica Drug Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Neuromyelitis Optica Drug Revenue Market Share (2021-2026)
Table 29. World Neuromyelitis Optica Drug Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Neuromyelitis Optica Drug Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Neuromyelitis Optica Drug Market Size by Type (2027-2032) & (USD Million)
Table 32. World Neuromyelitis Optica Drug Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 33. World Neuromyelitis Optica Drug Market Size by Application (2021-2026) & (USD Million)
Table 34. World Neuromyelitis Optica Drug Market Size by Application (2027-2032) & (USD Million)
Table 35. Pfizer Basic Information, Manufacturing Base and Competitors
Table 36. Pfizer Major Business
Table 37. Pfizer Neuromyelitis Optica Drug Product and Services
Table 38. Pfizer Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 39. Pfizer Recent Developments/Updates
Table 40. Pfizer Competitive Strengths & Weaknesses
Table 41. Fresenius Basic Information, Manufacturing Base and Competitors
Table 42. Fresenius Major Business
Table 43. Fresenius Neuromyelitis Optica Drug Product and Services
Table 44. Fresenius Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Fresenius Recent Developments/Updates
Table 46. Fresenius Competitive Strengths & Weaknesses
Table 47. Teva Basic Information, Manufacturing Base and Competitors
Table 48. Teva Major Business
Table 49. Teva Neuromyelitis Optica Drug Product and Services
Table 50. Teva Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Teva Recent Developments/Updates
Table 52. Teva Competitive Strengths & Weaknesses
Table 53. Sandoz Basic Information, Manufacturing Base and Competitors
Table 54. Sandoz Major Business
Table 55. Sandoz Neuromyelitis Optica Drug Product and Services
Table 56. Sandoz Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Sandoz Recent Developments/Updates
Table 58. Sandoz Competitive Strengths & Weaknesses
Table 59. Intas Basic Information, Manufacturing Base and Competitors
Table 60. Intas Major Business
Table 61. Intas Neuromyelitis Optica Drug Product and Services
Table 62. Intas Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Intas Recent Developments/Updates
Table 64. Intas Competitive Strengths & Weaknesses
Table 65. Gyjtrs Basic Information, Manufacturing Base and Competitors
Table 66. Gyjtrs Major Business
Table 67. Gyjtrs Neuromyelitis Optica Drug Product and Services
Table 68. Gyjtrs Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Gyjtrs Recent Developments/Updates
Table 70. Gyjtrs Competitive Strengths & Weaknesses
Table 71. NANG KUANG Basic Information, Manufacturing Base and Competitors
Table 72. NANG KUANG Major Business
Table 73. NANG KUANG Neuromyelitis Optica Drug Product and Services
Table 74. NANG KUANG Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. NANG KUANG Recent Developments/Updates
Table 76. NANG KUANG Competitive Strengths & Weaknesses
Table 77. Tianjin Kingyork Basic Information, Manufacturing Base and Competitors
Table 78. Tianjin Kingyork Major Business
Table 79. Tianjin Kingyork Neuromyelitis Optica Drug Product and Services
Table 80. Tianjin Kingyork Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Tianjin Kingyork Recent Developments/Updates
Table 82. Tianjin Kingyork Competitive Strengths & Weaknesses
Table 83. Baxter Basic Information, Manufacturing Base and Competitors
Table 84. Baxter Major Business
Table 85. Baxter Neuromyelitis Optica Drug Product and Services
Table 86. Baxter Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Baxter Recent Developments/Updates
Table 88. Baxter Competitive Strengths & Weaknesses
Table 89. CSL Basic Information, Manufacturing Base and Competitors
Table 90. CSL Major Business
Table 91. CSL Neuromyelitis Optica Drug Product and Services
Table 92. CSL Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. CSL Recent Developments/Updates
Table 94. CSL Competitive Strengths & Weaknesses
Table 95. Grifols Basic Information, Manufacturing Base and Competitors
Table 96. Grifols Major Business
Table 97. Grifols Neuromyelitis Optica Drug Product and Services
Table 98. Grifols Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Grifols Recent Developments/Updates
Table 100. Grifols Competitive Strengths & Weaknesses
Table 101. Octapharma Basic Information, Manufacturing Base and Competitors
Table 102. Octapharma Major Business
Table 103. Octapharma Neuromyelitis Optica Drug Product and Services
Table 104. Octapharma Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Octapharma Recent Developments/Updates
Table 106. Octapharma Competitive Strengths & Weaknesses
Table 107. CBOP Basic Information, Manufacturing Base and Competitors
Table 108. CBOP Major Business
Table 109. CBOP Neuromyelitis Optica Drug Product and Services
Table 110. CBOP Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. CBOP Recent Developments/Updates
Table 112. CBOP Competitive Strengths & Weaknesses
Table 113. Global Key Players of Neuromyelitis Optica Drug Upstream (Raw Materials)
Table 114. Global Neuromyelitis Optica Drug Typical Customers
LIST OF FIGURES
Figure 1. Neuromyelitis Optica Drug Picture
Figure 2. World Neuromyelitis Optica Drug Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Neuromyelitis Optica Drug Total Revenue (2021-2032) & (USD Million)
Figure 4. World Neuromyelitis Optica Drug Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Neuromyelitis Optica Drug Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Neuromyelitis Optica Drug Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Neuromyelitis Optica Drug Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Neuromyelitis Optica Drug Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Neuromyelitis Optica Drug Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Neuromyelitis Optica Drug Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Neuromyelitis Optica Drug Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Neuromyelitis Optica Drug Revenue (2021-2032) & (USD Million)
Figure 13. Neuromyelitis Optica Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 16. World Neuromyelitis Optica Drug Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 18. China Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 23. India Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Neuromyelitis Optica Drug by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Neuromyelitis Optica Drug Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Neuromyelitis Optica Drug Markets in 2025
Figure 27. United States VS China: Neuromyelitis Optica Drug Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Neuromyelitis Optica Drug Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Neuromyelitis Optica Drug Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Neuromyelitis Optica Drug Market Size Market Share by Type in 2025
Figure 31. Glucocorticoids
Figure 32. Immunotherapies
Figure 33. Others
Figure 34. World Neuromyelitis Optica Drug Market Size Market Share by Type (2021-2032)
Figure 35. World Neuromyelitis Optica Drug Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 36. World Neuromyelitis Optica Drug Market Size Market Share by Application in 2025
Figure 37. Acute Attack
Figure 38. Remission Prophylactic Treatment
Figure 39. World Neuromyelitis Optica Drug Market Size Market Share by Application (2021-2032)
Figure 40. Neuromyelitis Optica Drug Industrial Chain
Figure 41. Methodology
Figure 42. Research Process and Data Source
Figure 1. Neuromyelitis Optica Drug Picture
Figure 2. World Neuromyelitis Optica Drug Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Neuromyelitis Optica Drug Total Revenue (2021-2032) & (USD Million)
Figure 4. World Neuromyelitis Optica Drug Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Neuromyelitis Optica Drug Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Neuromyelitis Optica Drug Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Neuromyelitis Optica Drug Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Neuromyelitis Optica Drug Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Neuromyelitis Optica Drug Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Neuromyelitis Optica Drug Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Neuromyelitis Optica Drug Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Neuromyelitis Optica Drug Revenue (2021-2032) & (USD Million)
Figure 13. Neuromyelitis Optica Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 16. World Neuromyelitis Optica Drug Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 18. China Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 23. India Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Neuromyelitis Optica Drug by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Neuromyelitis Optica Drug Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Neuromyelitis Optica Drug Markets in 2025
Figure 27. United States VS China: Neuromyelitis Optica Drug Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Neuromyelitis Optica Drug Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Neuromyelitis Optica Drug Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Neuromyelitis Optica Drug Market Size Market Share by Type in 2025
Figure 31. Glucocorticoids
Figure 32. Immunotherapies
Figure 33. Others
Figure 34. World Neuromyelitis Optica Drug Market Size Market Share by Type (2021-2032)
Figure 35. World Neuromyelitis Optica Drug Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 36. World Neuromyelitis Optica Drug Market Size Market Share by Application in 2025
Figure 37. Acute Attack
Figure 38. Remission Prophylactic Treatment
Figure 39. World Neuromyelitis Optica Drug Market Size Market Share by Application (2021-2032)
Figure 40. Neuromyelitis Optica Drug Industrial Chain
Figure 41. Methodology
Figure 42. Research Process and Data Source
